Logo image of LXRX

LEXICON PHARMACEUTICALS INC (LXRX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:LXRX - US5288723027 - Common Stock

1.37 USD
+0.09 (+7.03%)
Last: 1/16/2026, 8:00:00 PM
1.35 USD
-0.02 (-1.46%)
After Hours: 1/16/2026, 8:00:00 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to LXRX. LXRX was compared to 191 industry peers in the Pharmaceuticals industry. The financial health of LXRX is average, but there are quite some concerns on its profitability. While showing a medium growth rate, LXRX is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • LXRX had negative earnings in the past year.
  • LXRX had a negative operating cash flow in the past year.
  • LXRX had negative earnings in each of the past 5 years.
  • LXRX had a negative operating cash flow in each of the past 5 years.
LXRX Yearly Net Income VS EBIT VS OCF VS FCFLXRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M -200M

1.2 Ratios

  • The Return On Assets of LXRX (-33.30%) is comparable to the rest of the industry.
  • The Return On Equity of LXRX (-57.07%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -33.3%
ROE -57.07%
ROIC N/A
ROA(3y)-65.6%
ROA(5y)-57.94%
ROE(3y)-138.18%
ROE(5y)-105.86%
ROIC(3y)N/A
ROIC(5y)N/A
LXRX Yearly ROA, ROE, ROICLXRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 400

1.3 Margins

  • With an excellent Gross Margin value of 99.41%, LXRX belongs to the best of the industry, outperforming 97.38% of the companies in the same industry.
  • LXRX's Gross Margin has been stable in the last couple of years.
  • LXRX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 99.41%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.67%
GM growth 5Y-0.19%
LXRX Yearly Profit, Operating, Gross MarginsLXRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K -80K -100K

More info and screens

4

2. Health

2.1 Basic Checks

  • LXRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • LXRX has more shares outstanding than it did 1 year ago.
  • LXRX has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for LXRX has been reduced compared to a year ago.
LXRX Yearly Shares OutstandingLXRX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
LXRX Yearly Total Debt VS Total AssetsLXRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

  • LXRX has an Altman-Z score of -10.27. This is a bad value and indicates that LXRX is not financially healthy and even has some risk of bankruptcy.
  • LXRX's Altman-Z score of -10.27 is on the low side compared to the rest of the industry. LXRX is outperformed by 72.77% of its industry peers.
  • A Debt/Equity ratio of 0.47 indicates that LXRX is not too dependend on debt financing.
  • LXRX has a worse Debt to Equity ratio (0.47) than 62.83% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.47
Debt/FCF N/A
Altman-Z -10.27
ROIC/WACCN/A
WACC10.2%
LXRX Yearly LT Debt VS Equity VS FCFLXRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

  • LXRX has a Current Ratio of 5.64. This indicates that LXRX is financially healthy and has no problem in meeting its short term obligations.
  • With a decent Current ratio value of 5.64, LXRX is doing good in the industry, outperforming 65.97% of the companies in the same industry.
  • LXRX has a Quick Ratio of 5.63. This indicates that LXRX is financially healthy and has no problem in meeting its short term obligations.
  • LXRX has a better Quick ratio (5.63) than 67.02% of its industry peers.
Industry RankSector Rank
Current Ratio 5.64
Quick Ratio 5.63
LXRX Yearly Current Assets VS Current LiabilitesLXRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

5

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 74.67% over the past year.
  • Looking at the last year, LXRX shows a very strong growth in Revenue. The Revenue has grown by 1255.21%.
  • Measured over the past years, LXRX shows a very negative growth in Revenue. The Revenue has been decreasing by -37.35% on average per year.
EPS 1Y (TTM)74.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%77.78%
Revenue 1Y (TTM)1255.21%
Revenue growth 3Y369.67%
Revenue growth 5Y-37.35%
Sales Q2Q%710.4%

3.2 Future

  • Based on estimates for the next years, LXRX will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.37% on average per year.
  • The Revenue is expected to grow by 57.00% on average over the next years. This is a very strong growth
EPS Next Y73.38%
EPS Next 2Y25.95%
EPS Next 3Y17.9%
EPS Next 5Y13.37%
Revenue Next Year328.76%
Revenue Next 2Y24.47%
Revenue Next 3Y32.02%
Revenue Next 5Y57%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
LXRX Yearly Revenue VS EstimatesLXRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M
LXRX Yearly EPS VS EstimatesLXRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 1 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for LXRX. In the last year negative earnings were reported.
  • Also next year LXRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LXRX Price Earnings VS Forward Price EarningsLXRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LXRX Per share dataLXRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1 0.2 -0.2 0.3

4.3 Compensation for Growth

  • A more expensive valuation may be justified as LXRX's earnings are expected to grow with 17.90% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.95%
EPS Next 3Y17.9%

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for LXRX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

LEXICON PHARMACEUTICALS INC

NASDAQ:LXRX (1/16/2026, 8:00:00 PM)

After market: 1.35 -0.02 (-1.46%)

1.37

+0.09 (+7.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06
Earnings (Next)03-04
Inst Owners71.86%
Inst Owner Change-0.01%
Ins Owners0.86%
Ins Owner Change0%
Market Cap497.86M
Revenue(TTM)70.86M
Net Income(TTM)-68.58M
Analysts80
Price Target2.94 (114.6%)
Short Float %6.5%
Short Ratio12.67
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)76.62%
Min EPS beat(2)40.58%
Max EPS beat(2)112.65%
EPS beat(4)4
Avg EPS beat(4)53.39%
Min EPS beat(4)29.61%
Max EPS beat(4)112.65%
EPS beat(8)7
Avg EPS beat(8)28.55%
EPS beat(12)9
Avg EPS beat(12)16.59%
EPS beat(16)13
Avg EPS beat(16)13.84%
Revenue beat(2)2
Avg Revenue beat(2)340.23%
Min Revenue beat(2)199.07%
Max Revenue beat(2)481.39%
Revenue beat(4)3
Avg Revenue beat(4)242.44%
Min Revenue beat(4)-12.42%
Max Revenue beat(4)481.39%
Revenue beat(8)3
Avg Revenue beat(8)102.48%
Revenue beat(12)4
Avg Revenue beat(12)80.36%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)4.73%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2.22%
EPS NY rev (1m)1.04%
EPS NY rev (3m)13.56%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-44.62%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-5.97%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.03
P/FCF N/A
P/OCF N/A
P/B 4.14
P/tB 6.58
EV/EBITDA N/A
EPS(TTM)-0.19
EYN/A
EPS(NY)-0.26
Fwd EYN/A
FCF(TTM)-0.2
FCFYN/A
OCF(TTM)-0.2
OCFYN/A
SpS0.2
BVpS0.33
TBVpS0.21
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -33.3%
ROE -57.07%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 99.41%
FCFM N/A
ROA(3y)-65.6%
ROA(5y)-57.94%
ROE(3y)-138.18%
ROE(5y)-105.86%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.67%
GM growth 5Y-0.19%
F-Score5
Asset Turnover0.34
Health
Industry RankSector Rank
Debt/Equity 0.47
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 75.48%
Cap/Sales 0.67%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.64
Quick Ratio 5.63
Altman-Z -10.27
F-Score5
WACC10.2%
ROIC/WACCN/A
Cap/Depr(3y)200.97%
Cap/Depr(5y)201.27%
Cap/Sales(3y)447.45%
Cap/Sales(5y)348.55%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)74.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%77.78%
EPS Next Y73.38%
EPS Next 2Y25.95%
EPS Next 3Y17.9%
EPS Next 5Y13.37%
Revenue 1Y (TTM)1255.21%
Revenue growth 3Y369.67%
Revenue growth 5Y-37.35%
Sales Q2Q%710.4%
Revenue Next Year328.76%
Revenue Next 2Y24.47%
Revenue Next 3Y32.02%
Revenue Next 5Y57%
EBIT growth 1Y68.33%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year71.1%
EBIT Next 3Y14.05%
EBIT Next 5YN/A
FCF growth 1Y46.08%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y45.74%
OCF growth 3YN/A
OCF growth 5YN/A

LEXICON PHARMACEUTICALS INC / LXRX FAQ

What is the fundamental rating for LXRX stock?

ChartMill assigns a fundamental rating of 3 / 10 to LXRX.


What is the valuation status of LEXICON PHARMACEUTICALS INC (LXRX) stock?

ChartMill assigns a valuation rating of 0 / 10 to LEXICON PHARMACEUTICALS INC (LXRX). This can be considered as Overvalued.


Can you provide the profitability details for LEXICON PHARMACEUTICALS INC?

LEXICON PHARMACEUTICALS INC (LXRX) has a profitability rating of 2 / 10.


Can you provide the financial health for LXRX stock?

The financial health rating of LEXICON PHARMACEUTICALS INC (LXRX) is 4 / 10.